ReviewHeliyon2024
Metabolic effects and clinical outcomes of olanzapine in schizophrenia: A systematic review and meta-analysis.
Review in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Beyond antipsychotic efficacy and toward an individualized therapeutic strategy: analysis of the systemic, metabolic, and inflammatory effects of olanzapine, haloperidol, and their combination in schizophrenic patients.Frontiers in pharmacology · 2026Article
- Drawbacks of Olanzapine Therapy: An Emphasis on Its Metabolic Effects and Discontinuation.Journal of clinical medicine · 2025Review
- Effect of olanzapine on changes in serum complement factors levels in patients with first-episode schizophrenia.BMC psychiatry · 2025Article
- Membrane Permeability Monitoring to Antipsychotic Olanzapine Using Platinum Black-Modified Electrodes.Sensors (Basel, Switzerland) · 2025Article
Corrections and comments
- Retracted
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the metabolic changes of patients with schizophrenia treated with olanzapine and analyze the correlation between the dosage of the drug, the blood concentration and the clinical response, so as to provide a reference for the clinical diagnosis and treatment. Methods: PubMed, web of science, Cochrane Library, MEDLINE databases were used to search for studies on olanzapine treatment in patients with schizophrenia, to extract changes in body weight, BMI, waist circumference, cholesterol, PANSS (The Positive and Negative Syndrome Scale), SAPS (The Positive Syndrome Scale), SANS (The Negative Syndrome Scale), BPRS (Brief Psychiatric Rating Scale), CGI (Clinical Global Impressions Ratings), and so on for meta-analysis, and to analyze the correlation of medication dose, blood concentration, and clinical response. Results: Twenty clinical trials (1839 participants, 1058 male and 781 female patients) were included in this meta-analysis. The results showed that patients receiving olanzapine had significant weight gain (WMD = 0.25, 95 % CI: 0.06-0.44) and no significant changes in HDL-C, LDL-C, triglycerides, or total cholesterol. They were significantly decreased in PANSS (WMD = -2.05, 95 % CI: -2.83, - 1.26), SAPS (WMD = -1.62, 95 % CI: -2.15, - 1.09), sans (WMD = -0.80, 95 % CI: -0.93, - 0.66), BPRS (WMD = -2.79, 95 % CI: -4.11, - 1.46), and CGI (WMD = -1.81, 95 % CI: -2.25, - 1.36). The dose of medication was positively associated with clinical response, with higher plasma concentrations at the recommended dose associated with better clinical outcomes (or = 2.91, 95 % CI: 1.36-6.27). When the body blood concentration is > 10 μg/L, the clinical response rate reaches about 80 %. Conclusion: The clinic can make an individualized medication regimen based on adjusting the dosage of drugs based on the results of the detection of blood concentration in the body under the premise of avoiding metabolic side effects to ensure the maximization of efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.